Legend Biotech
LEGN
194 hedge funds and large institutions have $5.81B invested in Legend Biotech in 2023 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 60 increasing their positions, 66 reducing their positions, and 15 closing their positions.
227% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 15
139% more call options, than puts
Call options by funds: $31.7M | Put options by funds: $13.3M
77% more capital invested
Capital invested by funds: $3.28B → $5.81B (+$2.53B)
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
21% more funds holding
Funds holding: 160 → 194 (+34)
5.21% more ownership
Funds ownership: 20.32% → 25.54% (+5.2%)
9% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 66
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$519M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$250M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$85.3M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$63.5M |
| 5 |
Holocene Advisors
New York
|
+$59.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
-$53.2M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$31.8M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$26M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$24.1M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$21M |
LEGN Hedge Fund Activity: Q2 2023 in Review
194 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q2 2023, worth a combined $5.81B — up 77% from $3.28B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new LEGN positions and 15 closed out — a net gain of 34 holders — while 60 added to existing stakes and 66 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $519M. The largest seller was Johnson & Johnson, cutting an estimated $53.2M.
- 194 institutional investors held Legend Biotech (LEGN) as of Q2 2023, up from 160 in Q1 2023.
- Funds reported $5.81B of Legend Biotech stock for Q2 2023, up 77% quarter-over-quarter.
- 49 funds opened new Legend Biotech positions in Q2 2023 and 15 closed out, a net change of +34 holders.
- The largest Legend Biotech buyer in Q2 2023 was T. Rowe Price Associates, an estimated $519M added.
- The largest Legend Biotech seller in Q2 2023 was Johnson & Johnson, an estimated $53.2M sold.
Based on aggregated 13F filings for Q2 2023.